Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback